title: Assessing long-term health and cost outcomes of patient-centered medical homes serving adults with poor diabetes control.
abstract: The patient-centered medical home (PCMH) is an integrated primary care delivery model particularly suited for patients with poor diabetes control. Although PCMH models targeting adults with diabetes have shown some early success, little is known about the long-term benefits of medical homes in terms of health and cost outcomes. The performance of a PCMH model in adults with poor diabetes control was assessed using simulated controlled trial data obtained from the Archimedes model of disease progression and health care utilization. Using the Cardio-Metabolic Risk data set, we compared health and cost outcomes over a 20-year period between adults with poor diabetes control (HbA1c >9%) receiving standard care and these same adults receiving care under a PCMH model with a 49% HbA1c intervention improvement rate at a per-beneficiary per-month care management cost of $20 per month. The results suggest that the PCMH model has the potential to not only reduce the proportion of the population with bilateral blindness, foot amputations, and myocardial infarctions-and the mortality rate-but it can also do so in a cost-effective manner ($7898 per quality-adjusted life year). The PCMH model is cost saving for the population 50 to 64 years old and it is particularly cost-effective for men ($883 per quality-adjusted life year). Moreover, these effects are relatively large for adults 30 to 49 years old (lower bilateral blindness and death rates), women (lower foot amputation and death rates), and men (lower bilateral blindness and myocardial infarction rates). The PCMH model has potential long-term benefits to both patients with poor diabetes control as well as health care systems and providers willing to invest in this health care delivery approach.
authors.affiliation: University of North Texas Health Science Center, Fort Worth, TX, USA.
authors.forename: José A
authors.initials: JA
authors.lastname: Pagán
authors.forename: Erin K
authors.initials: EK
authors.lastname: Carlson
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000671:Amputation, Surgical; D001766:Blindness / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control; D003362:Cost-Benefit Analysis; D048909:Diabetes Complications / Q000191:economics / Q000517:prevention & control*; D003920:Diabetes Mellitus / Q000191:economics / Q000378:metabolism / Q000628:therapy*; D005260:Female; D006442:Glycated Hemoglobin / Q000378:metabolism*; D017048:Health Care Costs; D006801:Humans; D008297:Male; D008875:Middle Aged; D009026:Mortality; D009203:Myocardial Infarction / Q000453:epidemiology / Q000209:etiology; D018802:Patient-Centered Care / Q000191:economics / Q000379:methods*; D011320:Primary Health Care / Q000191:economics / Q000379:methods*; D019057:Quality-Adjusted Life Years; D059039:Standard of Care
chemical_list: D006442:Glycated Hemoglobin
keywords: cost-effectiveness analysis; diabetes; disease management; health outcomes; medical home